🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Berlin
Clinical trial register · Germany

Clinical Trials in Berlin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca115 Charite University, Berlin, Germany93 Janssen Research & Development, LLC49 Eli Lilly and Company45 Novartis Pharmaceuticals45
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Berlin

1584 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
NCT07284420AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG
DrugsEmpasiprubart·Efgartigimod
argenx
Phase 2
70
Berlin, Göttingen, Würzburg
2025-12-19
Recruiting
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
NCT07237256Breast Cancer
UNICANCER
Phase 3
3,902
Aachen, Augsburg, Bad Nauheim, Berlin, Bremen, Cottbus, Dresden, Düsseldorf
2025-12-18
Recruiting
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
NCT07314164Neuroendocrine Tumors
Ipsen
Observational
150
Aschaffenburg, Berlin, Bonn, Bremen, Chemnitz, Cologne, Dresden, Erlangen
2025-12-17
Recruiting
WATCHMAN FLX Pro European Registry
NCT07262255Non-valvular Atrial Fibrillation (AF), Left Atrial Appendage Closure
Boston Scientific Corporation
Observational
1,000
Bad Oeynhausen, Berlin, Erfurt, Hamburg, Lübeck
2025-12-17
Recruiting
Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
NCT07301736Asthma
Chiesi Farmaceutici S.p.A.
Phase 2
780
Ahrensburg, Berlin, Cottbus, Delitzsch, Düsseldorf, Hamburg, Ibbenbueren, Leipzig
2025-12-17
Recruiting
Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities
NCT06722183Colorectal Cancer
DrugTislelizumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
33
Amberg, Berlin, Düsseldorf, Essen, Frankfurt am Main, Hamburg, Mainz, München
2025-12-16
Recruiting
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
NCT07280585Polycystic Kidney, Autosomal Dominant
DrugDapagliflozin
University of Cologne
Phase 3
420
Stuttgart, Nuremberg, Aachen, Berlin, Cologne, Dortmund, Dresden, Düsseldorf
2025-12-16
Recruiting
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
NCT07276581Rheumatoid Arthritis
AstraZeneca
Phase 2
320
Bad Doberan, Berlin, Hamburg, Sendenhorst
2025-12-15
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600Overweight, Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
1,035
Berlin, Bünde, Essen, Hamburg, Münster, Oldenburg
2025-12-15
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site
DrugsPF-08634404·Avastin·Bevacizumab
Pfizer
Phase 3
800
Frankfurt am Main, Leipzig, Berlin, Dresden, Hamburg, München
2025-12-11
Active, closed
Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
NCT07228403Short Bowel Syndrome (SBS)
DrugGlepaglutide
Zealand Pharma
Phase 3
28
Frankfurt am Main, Rostock, Bonn, Berlin, Hamburg
2025-12-11
Recruiting
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
NCT07290036Psoriatic Arthritis, Axial Spondyloarthritis
UCB Biopharma SRL
Phase 1
392
Berlin, Hamburg, Ratingen, Wetzlar
2025-12-10
Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
DrugCYB003
Cybin IRL Limited
Phase 3
330
Homburg, Berlin, Frankfurt am Main, Mannheim
2025-12-10
Recruiting
Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support
NCT06910943Choline Deficiency, Liver Injury
Protara Therapeutics
Phase 2/3
129
Berlin, Essen
2025-12-10
Recruiting
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
NCT07285213Clostridioides Difficile Infection
AstraZeneca
Phase 2
230
Augsburg, Berlin, Cologne, Frankfurt, Hamburg, Jena, Leipzig, München
2025-12-10
Recruiting
A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
NCT07255638Indolent Systemic Mastocytosis
DrugAvapritinib
Blueprint Medicines Corporation
Observational
80
Berlin, Bochum, Deggendorf, Dresden, Göttingen, Tübingen, Wiesbaden, Wuppertal
2025-12-09
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779Ovarian Cancer
DrugINCB123667
Incyte Corporation
Phase 3
466
Berlin, Bonn, Dresden, Essen, Kassel, Kiel, Mannheim, Minden
2025-12-09
Recruiting
Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure
NCT07038356Acute Decompensated Heart Failure (ADHF)
DrugDapagliflozin
Christian Schulze
Phase 3
536
Jena, Bad Nauheim, Berlin, Bonn, Dresden, Göttingen, Halle, Leipzig
2025-12-08
Recruiting
Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children
NCT07193719Congenital Heart Disease, Cardiopulmonary Bypass, Cardiac Surgery, Mechanical Ventilation
Charite University, Berlin, Germany
Phase 1/2
80
Berlin
2025-12-05
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab
AstraZeneca
Phase 3
1,100
Aachen, Berlin, Bonn, Düsseldorf, Essen, Frankfurt, Freiburg im Breisgau, Hamburg
2025-12-04
Recruiting
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
NCT07209111Neoplasm Malignant
DrugsCalderasib·Cetuximab
Merck Sharp & Dohme LLC
Phase 2
150
Leipzig, Jena, Berlin
2025-12-04
Recruiting
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
NCT07276724Severe Asthma
DrugGB-0895
Generate Biomedicines
Phase 3
786
Deggingen, München, Frankfurt am Main, Witten, Leipzig, Lübeck, Berlin
2025-12-03
Recruiting
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
NCT07218926Gastrointestinal Neoplasms
DrugsIDRX-42·Sunitinib
GlaxoSmithKline
Phase 3
450
München, Cologne, Essen, Dresden, Berlin, Mannheim, Tübingen
2025-12-03
Recruiting
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453Plaque Psoriasis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
366
Münster, Mainz, Berlin, Dresden, Erlangen
2025-12-03
Active, closed
A Study of DII235 in Adults With Elevated Lipoprotein(a)
NCT07235046Lipoprotein Disorder
Novartis Pharmaceuticals
Phase 2
234
Munich, Potsdam, Frankfurt am Main, Kaiserslautern, Dresden, Bad Krozingen, Bad Oeynhausen, Berlin
2025-12-02
Recruiting
A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis
NCT07258849Rheumatoid Arthritis (RA)
Eli Lilly and Company
Phase 1
141
Berlin
2025-12-02
Recruiting
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
NCT07116031Chronic Graft Versus Host Disease
DrugBelumosudil
Sanofi
Phase 2
37
Berlin
2025-12-02
Recruiting
Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice
NCT07302802Monogenic Obesity
DrugSemaglutide
Prof. Dr. Martin Wabitsch
Observational
70
Berlin, Leipzig, Ulm
2025-12-01
Not yet open
Establishment of 2D and 3D Primary Cell Cultures From Gastric and Gastroesophageal Junction Cancer
NCT05541874Gastric and Gastroesophageal Junction Cancer
Charite University, Berlin, Germany
Observational
13
Berlin
2025-12
Not yet open
WELT-REST: WELT Randomized Evaluation of Sleep Therapy
NCT07289217Insomnia
WELT corp
Not applicable
80
Berlin
2025-12
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146Small-cell Lung Cancer
DrugZL-1310
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Frankfurt am Main, Berlin, Dresden, Halle
2025-11-30
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674Metastatic Castration-resistant Prostate Cancer
DrugsXaluritamig·Cabazitaxel·Abiraterone acetate·Docetaxel
Amgen
Phase 3
750
Berlin, Bonn, Dresden, Erlangen, Essen, Hamburg, Heidelberg, Jena
2025-11-28
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
NCT07166094Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
DrugRina-S
Genmab
Phase 3
660
Hamburg, Lemgo, Berlin
2025-11-28
Recruiting
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
NCT07236099Prurigo Nodularis (PN)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
135
Berlin, Darmstadt, Leipzig, Mainz
2025-11-27
Recruiting
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
NCT07160608Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Alexion Pharmaceuticals, Inc.
Phase 2
75
Berlin, Essen, Göttingen, Ludwigshafen, München
2025-11-26
Recruiting
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
NCT06930625Acromegaly
Debiopharm International SA
Phase 3
119
Berlin, Munich, Würzburg
2025-11-26
Recruiting
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT07155174Small Cell Lung Cancer
DrugsABBV-706·Lurbinectedin·Etoposide·Atezolizumab
AbbVie
Phase 2
180
Immenhausen, Marburg, Berlin
2025-11-25
Recruiting
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
NCT07142291Amyotrophic Lateral Sclerosis (ALS)
DrugsCromolyn Sodium·Riluzole
PhenoNet, Inc.
Phase 2
105
Berlin, Hanover, Lübeck
2025-11-25
Recruiting
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
NCT07226765Obstructive Sleep Apnea
DrugMaridebart cafraglutide
Amgen
Phase 3
250
Berlin, Essen, Hamburg, Hanover, Karlsruhe, Oldenburg
2025-11-25
Active, closed
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
NCT07217015Atopic Dermatitis
DrugKT-621
Kymera Therapeutics, Inc.
Phase 2
200
Augsburg, München, Bad Bentheim, Berlin, Dresden, Frankfurt, Friedrichshafen, Mainz
2025-11-24
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310Parkinson's Disease
DrugPrasinezumab
Hoffmann-La Roche
Phase 3
900
Beelitz, Berlin, Bochum, Dresden, Düsseldorf, Erlangen, Freiburg im Breisgau, Hanover
2025-11-24
Recruiting
A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation
NCT07073950Chronic Obstructive Pulmonary Disease, Hyperinflation
AstraZeneca
Phase 4
56
Ahrensburg, Berlin, Frankfurt, Hanover
2025-11-24
Recruiting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease
NCT07235059Chronic Kidney Disease
Novartis Pharmaceuticals
Phase 1
112
Berlin
2025-11-20
Active, closed
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
NCT07211685Alport Syndrome
Bayer
Phase 2
60
Erlangen, Göttingen, Cologne, Berlin
2025-11-19
Active, closed
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vertex Pharmaceuticals Incorporated
Phase 2
26
Berlin, Cologne
2025-11-19
Recruiting
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
NCT07228832Metastatic Colorectal Cancer (CRC)
DrugsIvonescimab·Leucovorin·Adrucil·Oxaliplatin
Summit Therapeutics
Phase 3
600
Berlin, Bonn, Hamburg
2025-11-18
Recruiting
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
NCT07219420Palmoplantar Pustulosis
DrugBimekizumab
UCB Biopharma SRL
Phase 3
320
Ahaus, Bad Bentheim, Berlin, Bielefeld, Bochum, Dresden, Göttingen, Kiel
2025-11-14
Recruiting
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NCT06804811NonSegmental Vitiligo
DrugRuxolitinib
Incyte Corporation
Phase 3
250
Berlin, Erlangen, Hamburg, Kiel, Leipzig, Mainz, München, Münster
2025-11-13
Active, closed
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT07074886Multiple Sclerosis
Hoffmann-La Roche
Phase 2
193
Berlin, Bochum, Dresden, Tübingen
2025-11-13
Active, closed
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150Alzheimers Disease
DrugTrontinemab
Hoffmann-La Roche
Phase 3
1,060
Erlangen, Berlin, Bonn, Cologne, Dresden, Homburg/Saar, Jena, Leipzig
2025-11-12
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101Ulcerative Colitis
DrugsZotemtegrast·Mirikizumab
Eli Lilly and Company
Phase 2
252
Berlin, Dachau, Erlangen, Regensburg, Ulm
2025-11-10
Recruiting
Safety and Efficacy of hUC-MSC for the Treatment of Cartilage Damage in the Knee Joint
NCT06981741Cartilage Damage
BIONCaRT GmbH
Phase 1/2
55
Altenburg, Andernach, Bamberg, Berlin, Dinslaken, Dresden, Greven
2025-11-10
Active, closed
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT07220577Atopic Dermatitis
DrugGIA632
Novartis Pharmaceuticals
Phase 2
34
Berlin, Hamburg, Mainz
2025-11-10
Recruiting
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization
DrugAZD0292
AstraZeneca
Phase 2
435
Berlin, Darmstadt, Essen, Frankfurt, Halle, Hanover, Konstanz, München
2025-11-06
Recruiting
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
NCT07015242Lymphoma
DrugsProcarbazine·Breyanzi·Calcium folinate·Temozolomide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
65
Freiburg im Breisgau, Ulm, Cologne, Essen, Chemnitz, Berlin, Göttingen, Hamburg
2025-11-06
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080Non-Small Cell Lung Cancer
DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
500
Esslingen am Neckar, Stuttgart, Donauwörth, Oldenburg, Cologne, Chemnitz, Kiel, Berlin
2025-11-05
Recruiting
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT07197307Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B
Universität Münster
Phase 2
120
Aachen, Augsburg, Berlin, Bielefeld, Chemnitz, Düsseldorf, Erlangen, Essen
2025-10-31
Recruiting
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
NCT07219615Chronic Spontaneous Urticaria
DrugsLitfulo·Ritlecitinib
Pfizer
Phase 2
200
Stuttgart, Münster, Berlin, Dresden, Leipzig, Wuppertal
2025-10-30
Recruiting
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051Bronchiectasis
DrugGSK3862995B
GlaxoSmithKline
Phase 2
363
Bendorf, Berlin, Frankfurt, Geesthacht, Hamburg, München
2025-10-30
Recruiting
Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
NCT07026474Recurrent Head and Neck Squamous Cell Carcinoma
DrugsAdrucil·Cisplatin·Pembrolizumab
Universität des Saarlandes
Phase 3
214
Berlin, Chemnitz, Darmstadt, Dresden, Erfurt, Erlangen, Frankfurt am Main, Giessen
2025-10-30
Recruiting
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
NCT06934967Paroxysmal Nocturnal Hemoglobinuria (PNH)
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
12
Cologne, Berlin
2025-10-28
Recruiting
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
NCT07217067Atrial Fibrillation
Novartis Pharmaceuticals
Phase 2
165
Bad Homburg, Berlin, Hamburg
2025-10-28
Recruiting
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
NCT06856837Metastatic Colorectal Cancer
DrugsLonsurf·Trifluridine/Tipiracil·Fruquintinib·Avastin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
140
Amberg, Bad Saarow, Berlin, Bochum, Düsseldorf, Essen, Frankfurt, Frankfurt am Main
2025-10-27
Recruiting
Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease
NCT07151378PARKINSON DISEASE (Disorder)
University Hospital Tuebingen
Phase 3
150
Saarlouis, Berlin, Bottrop, Dresden, Marburg, Tübingen, Wolfach
2025-10-27
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin
Hoffmann-La Roche
Phase 3
600
Berlin, Dresden, Essen, Esslingen am Neckar, Gauting, Großhansdorf, Halle, Hamburg
2025-10-24
Recruiting
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
NCT07220564Haemophilia A
Novo Nordisk A/S
Phase 1
30
Berlin, Bonn, Hanover
2025-10-23
Active, closed
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Pancreatic Ductal Adenocarcinoma
DrugsNavlimetostat·Nab-paclitaxel·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
470
München, Frankfurt am Main, Göttingen, Bochum, Chemnitz, Dresden, Berlin, Cologne
2025-10-23
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173Asthma
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Bendorf, Berlin, Essen, Frankfurt, Hamburg, Leipzig, Mainz, Offenbach
2025-10-22
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
DrugsMIRV·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine
Eli Lilly and Company
Phase 3
1,630
Aachen, Berlin, Bonn, Cologne, Dresden, Düsseldorf, Erlangen, Essen
2025-10-22
Recruiting
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339Pulmonary Disease, Chronic Obstructive
DrugDepemokimab
GlaxoSmithKline
Phase 3
1,196
Berlin, Frankfurt, Mainz, München
2025-10-20
Recruiting
Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
NCT07407465Colorectal Cancer, Colorectal Adenocarcinoma, Rectal Adenocarcinoma, Rectal Cancer, Adenocarcinoma
DrugsTrastuzumab deruxtecan·Capecitabine·Bevacizumab
Gruppo Oncologico del Nord-Ovest
Phase 2
42
Berlin, Frankfurt
2025-10-20
Recruiting
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
NCT07194850Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura
DrugEfgartigimod
argenx
Phase 2/3
24
Berlin, Freiburg im Breisgau
2025-10-20
Recruiting
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953Alcohol Use Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,100
Berlin, Dresden, Hamburg, Mannheim, Offenbach, Schwerin
2025-10-16
Recruiting
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
NCT07266805Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
DrugDeucrictibant
Pharvaris Netherlands B.V.
Phase 3
48
Berlin, Frankfurt am Main, Munich
2025-10-16
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966Alcohol Use Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,100
Berlin, Dresden, Hamburg, Mannheim, Offenbach, Schwerin
2025-10-15
Recruiting
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
NCT07115004Von Willebrand Disease (VWD)
DrugVGA039
Vega Therapeutics, Inc
Phase 3
60
Berlin, Frankfurt
2025-10-15
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
4,500
Bad Oeynhausen, Berlin, Brandenburg, Dresden, Düsseldorf, Frankfurt, Hanover, Heidelberg
2025-10-15
Recruiting
A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies
NCT07231458Advanced Solid Tumors
DrugPembrolizumab
Abalos Therapeutics GmbH
Phase 1
27
Berlin, Tübingen
2025-10-14
Recruiting
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
NCT06997588PIK3CA-related Overgrowth Spectrum (PROS)
DrugAlpelisib
Novartis Pharmaceuticals
Phase 2
104
Freiburg im Breisgau, Düsseldorf, Leipzig, Halle, Berlin, Stuttgart
2025-10-09
By invitation
Clinical Impact Through AI-assisted MS Care - A Prospective Multi-center Study
NCT07032246Multiple Sclerosis, Radiologically Isolated Syndrome, Clinically Isolated Syndrome
icometrix
Not applicable
750
Bochum, Dresden, Berlin
2025-10-09
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07184996Ulcerative Colitis
DrugDuvakitug
Sanofi
Phase 3
980
Berlin, Herne, Kiel, Leipzig, Minden, Ulm
2025-10-08
Active, closed
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
NCT07176390Arthritis, Rheumatoid
DrugsTulisokibart·Methotrexate
Merck Sharp & Dohme LLC
Phase 2
185
München, Cottbus, Ratingen, Berlin, Hamburg
2025-10-08
Recruiting
Study to Evaluate the Performance of Navigated TKA With OrthoPilot® pheno4u TKA Level 1
NCT06955481Osteoarthritis, Knee, Joint Diseases, Rheumatoid Arthritis of Knee, Posttraumatic Arthropathy
Aesculap AG
Observational
120
Konstanz, Berlin, Dresden
2025-10-07
Recruiting
A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria
NCT07181369Healthy Subjects, Cold Urticaria, Symptomatic Dermographism, Chronic Inducible Urticaria
Granular Therapeutics Limited
Phase 1
72
Berlin, Halle
2025-10-06
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 2/3
1,092
Berlin, Dachau, Erlangen, Halle, Hanover, Jerichow, Kiel, Leipzig
2025-10-03
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
DrugPonsegromab
Pfizer
Phase 2/3
982
München, Düsseldorf, Dresden, Leipzig, Berlin
2025-10-03
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)
DrugNNC6019-0001
Novo Nordisk A/S
Phase 3
1,280
Bad Oeynhausen, Berlin, Cologne, Dresden, Frankfurt am Main, Freiburg im Breisgau, Jena, Kiel
2025-10-02
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
882
Aachen, Berlin, Dachau, Erlangen, Halle, Hanover, Jerichow, Kiel
2025-10-01
Recruiting
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT05745714Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
DrugsRuxolitinib·Cytarabine·Venetoclax·Dexamethasone
Princess Maxima Center for Pediatric Oncology
Phase 1/2
26
Augsburg, Berlin, Essen, Frankfurt, Münster
2025-10-01
Recruiting
#AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial.
NCT06900829HIV Infection, HIV, Stigma, Education
Casper Rokx
Not applicable
5,200
Berlin, Cologne, München
2025-10-01
Active, closed
CIRCA-MED WP1 & WP3 - Circadian Rhythms in ICU Patients
NCT07811492Circadian Rhythm
Charite University, Berlin, Germany
Observational
25,000
Berlin
2025-10-01
Recruiting
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT05751044Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
DrugsDasatinib·Cytarabine·Venetoclax·Dexamethasone
Princess Maxima Center for Pediatric Oncology
Phase 1/2
26
Augsburg, Berlin, Essen, Frankfurt, Münster
2025-10-01
Not yet open
Protoporphyrin Imaging in Multispectral Evaluation of Resections
NCT07021573Glioma
Medical University Innsbruck
Not applicable
80
Berlin, Freiburg im Breisgau, Göttingen, München, Münster, Tübingen
2025-09-30
Active, closed
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
NCT07187375Congenital Adrenal Hyperplasia
DrugCrinecerfont
Neurocrine Switzerland GmbH
Phase 2
7
Berlin, Düsseldorf, Heidelberg
2025-09-30
Recruiting
Treatment Guided by Comprehensive Genome and Transcriptome Analysis Versus Standard of Care in Advanced Rare Cancers
NCT06855134Rare Cancer
German Cancer Research Center
Observational
946
Augsburg, Berlin, Cologne, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hamburg
2025-09-29
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsMevrometostat·Xtandi·Enzalutamide
Pfizer
Phase 3
1,000
Heidelberg, Nürtingen, Ulm, Mettmann, Lübeck, Berlin, Düsseldorf, Hamburg
2025-09-28
Recruiting
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
NCT07190196Immunoglobulin G4 Related Disease
DrugRilzabrutinib
Sanofi
Phase 3
124
Berlin, Erlangen, Hanover, Minden, Ulm
2025-09-26
Recruiting
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
NCT07133633Radiographic Axial Spondyloarthritis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
315
Munich, Cottbus, Herne, Ratingen, Berlin, Hamburg
2025-09-26
Recruiting
Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)
NCT07290257Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis
DrugMaralixibat
Mirum Pharmaceuticals, Inc.
Phase 4
230
Berlin, Essen, Hamburg
2025-09-25
Recruiting
Post-intensive Care Syndromes in Pregnant Patients With Respiratory Failure and COVID-19 Compared to Non-pregnant Patients With Respiratory Failure and COVID-19
NCT07051967COVID-19, Acute Respiratory Distress Syndrome Due to COVID-19, Pregnancy Related
Charite University, Berlin, Germany
Observational
40
Berlin
2025-09-22
Rows per page Showing 201–300 of 1584
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/berlin?page=3

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,584 of those studies with a site in Berlin.

How many clinical trials are recruiting in Berlin?

844 of the 1,584 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 47 have not yet opened recruitment, 660 are active but closed to new participants, and 33 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.